BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

557 related articles for article (PubMed ID: 29159783)

  • 1. In Vitro Study of the Effects of Denosumab on Giant Cell Tumor of Bone: Comparison with Zoledronic Acid.
    Shibuya I; Takami M; Miyamoto A; Karakawa A; Dezawa A; Nakamura S; Kamijo R
    Pathol Oncol Res; 2019 Jan; 25(1):409-419. PubMed ID: 29159783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of RANKL Expression in Osteocyte-like Differentiated Tumor Cells in Giant Cell Tumor of Bone After Denosumab Treatment.
    Noguchi T; Sakamoto A; Murotani Y; Murata K; Hirata M; Yamada Y; Toguchida J; Matsuda S
    J Histochem Cytochem; 2023 Mar; 71(3):131-138. PubMed ID: 36971322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bisphosphonate treatment of aggressive primary, recurrent and metastatic Giant Cell Tumour of Bone.
    Balke M; Campanacci L; Gebert C; Picci P; Gibbons M; Taylor R; Hogendoorn P; Kroep J; Wass J; Athanasou N
    BMC Cancer; 2010 Aug; 10():462. PubMed ID: 20799989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant Zoledronic Acid in High-Risk Giant Cell Tumor of Bone: A Multicenter Randomized Phase II Trial.
    Lipplaa A; Kroep JR; van der Heijden L; Jutte PC; Hogendoorn PCW; Dijkstra S; Gelderblom H
    Oncologist; 2019 Jul; 24(7):889-e421. PubMed ID: 31040253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Giant cell tumours of bone treated with denosumab: histological, immunohistochemical and H3F3A mutation analyses.
    Kato I; Furuya M; Matsuo K; Kawabata Y; Tanaka R; Ohashi K
    Histopathology; 2018 May; 72(6):914-922. PubMed ID: 29206281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current concepts in the treatment of giant cell tumour of bone.
    van der Heijden L; Dijkstra S; van de Sande M; Gelderblom H
    Curr Opin Oncol; 2020 Jul; 32(4):332-338. PubMed ID: 32541321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Denosumab may be a supplement to the surgical treatment of giant cell tumours of bone].
    Sørensen AL; Hansen RL; Jørgensen PH
    Ugeskr Laeger; 2016 Sep; 178(36):. PubMed ID: 27593237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Receptor-Activator of Nuclear KappaB Ligand Expression as a New Therapeutic Target in Primary Bone Tumors.
    Yamagishi T; Kawashima H; Ogose A; Ariizumi T; Sasaki T; Hatano H; Hotta T; Endo N
    PLoS One; 2016; 11(5):e0154680. PubMed ID: 27163152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spectrum of histological features of Denosumab treated Giant Cell Tumor of Bone; potential pitfalls and diagnostic challenges for pathologists.
    Tariq MU; Umer M; Khan Z; Saeed J; Siddiqui MA; Din NU
    Ann Diagn Pathol; 2020 Apr; 45():151479. PubMed ID: 32088577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bortezomib Inhibits Giant Cell Tumor of Bone through Induction of Cell Apoptosis and Inhibition of Osteoclast Recruitment, Giant Cell Formation, and Bone Resorption.
    Xu L; Luo J; Jin R; Yue Z; Sun P; Yang Z; Yang X; Wan W; Zhang J; Li S; Liu M; Xiao J
    Mol Cancer Ther; 2016 May; 15(5):854-65. PubMed ID: 26861247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Denosumab treated giant cell tumour of bone: a morphological, immunohistochemical and molecular analysis of a series.
    Girolami I; Mancini I; Simoni A; Baldi GG; Simi L; Campanacci D; Beltrami G; Scoccianti G; D'Arienzo A; Capanna R; Franchi A
    J Clin Pathol; 2016 Mar; 69(3):240-7. PubMed ID: 26338802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phenotypic and molecular studies of giant-cell tumors of bone and soft tissue.
    Lau YS; Sabokbar A; Gibbons CL; Giele H; Athanasou N
    Hum Pathol; 2005 Sep; 36(9):945-54. PubMed ID: 16153456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Giant cell tumour of bone in the denosumab era.
    van der Heijden L; Dijkstra PDS; Blay JY; Gelderblom H
    Eur J Cancer; 2017 May; 77():75-83. PubMed ID: 28365529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone.
    Branstetter DG; Nelson SD; Manivel JC; Blay JY; Chawla S; Thomas DM; Jun S; Jacobs I
    Clin Cancer Res; 2012 Aug; 18(16):4415-24. PubMed ID: 22711702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular and cellular mechanisms for zoledronic acid-loaded magnesium-strontium alloys to inhibit giant cell tumors of bone.
    Li M; Wang W; Zhu Y; Lu Y; Wan P; Yang K; Zhang Y; Mao C
    Acta Biomater; 2018 Sep; 77():365-379. PubMed ID: 30030174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Denosumab Induces Neoplastic Stromal Cell Apoptosis
    Chen X; Ye F; He H; Chen G; Chen Z; Ye E; He B; Yang Y; Zhang J
    Curr Cancer Drug Targets; 2024; 24(5):565-578. PubMed ID: 37961860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histone H3.3 mutation in giant cell tumor of bone: an update in pathology.
    Yamamoto H; Ishihara S; Toda Y; Oda Y
    Med Mol Morphol; 2020 Mar; 53(1):1-6. PubMed ID: 31748824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preoperative Denosumab plus Surgery in the Management of Giant Cell Tumor of Bone: A Comprehensive Narrative Literature Review.
    Abu-Zaid A; Alaqaili SI; Ahmad SO; Bin Hazzaa I; Alharbi H
    Gulf J Oncolog; 2019 May; 1(30):67-75. PubMed ID: 31242985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Objective tumor response to denosumab in patients with giant cell tumor of bone: a multicenter phase II trial.
    Ueda T; Morioka H; Nishida Y; Kakunaga S; Tsuchiya H; Matsumoto Y; Asami Y; Inoue T; Yoneda T
    Ann Oncol; 2015 Oct; 26(10):2149-54. PubMed ID: 26205395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histological and immunohistochemical analyses of osteoclast maturation in giant cell tumor of bone.
    Agawa R; Kato I; Kawabata Y; Takeyama M; Fujii S
    Pathol Res Pract; 2024 Feb; 254():155128. PubMed ID: 38244437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.